Actym Therapeutics Announces Participation in May Investor Conferences

BERKELEY, CA – May 3, 2022 – PRNewswire

Actym Therapeutics, a privately held biotechnology company focused on the discovery and development of novel immunotherapies to treat cancer, announced today that CEO Christopher Thanos will present at the following investor conferences in May 2022:

Longwood Healthcare Leaders Date: May 5 Time: 3:40 PM ET / 12:40 PM PT Event: NOVEL THERAPEUTIC MODALITIES

Sachs 8th Annual Immuno-Oncology Innovation Forum Date: May 24-25 Time: TBD Event: SPOTLIGHT

About Actym

Actym Therapeutics, based in Berkeley, CA, is a privately-held biotechnology company focused on discovery and development of novel immuno-oncology therapies to treat cancer. The company has developed an attenuated, microbial-based, immunotherapeutic technology platform called STACT (S. Typhimurium-Attenuated Cancer Therapy). In preclinical studies, STACT specifically enriches in many types of solid tumors and not in healthy tissue. Once there, STACT delivers multiplexed immuno-modulatory payloads directly to tumor-resident immune cells. Many of these payload targets are of significant interest to the biopharmaceutical community but are intractable using conventional approaches due to systemic toxicities after intravenous dosing. Furthermore, STACT has been engineered to deliver payload combinations, which facilitates engagement of multiple biological pathways from a single therapy. In April of 2020, Actym raised $34 million in a Series A financing, co-led by Boehringer-Ingelheim Venture Fund and Panacea Venture Healthcare, with participation from Illumina Ventures, Korea Investment Partners, and JLO Ventures.

For more information, please contact: ​

Actym Therapeutics: Valerie Enes Seismic Media Relations valerie@teamseismic.com​

Corporate Contact: Sheriese Rush, MBA Head of Operations, Actym Therapeutics srush@actymthera.com